Melhem M.Solh, M.D.

<<Back To Our Physicians

Dr. Melhem Sohl

Melhem Solh, M.D., is board certified in the subspecialties of medical oncology and hematology. He is the Medical Director for the Cellular Therapy Program at Northside Hospital. Dr. Solh is also a Northside Hospital Blood and Marrow Transplant and Leukemia Program physician. Dr. Solh has been Atlanta's Top Doctor in his specialty from 2013 to 2024.

Training

  • American University of Beirut, Beirut, Lebanon, Bachelor of Science in Chemistry

  • American University of Beirut, Beirut, Lebanon, Doctor of Medicine

  • Residency training, Wayne State University, Detroit Medical Center (Grace Hospital)

  • Fellowships: Hematology- Oncology and Blood and Marrow Transplant, University of Minnesota Medical Center, Minneapolis, MN

Society Memberships

  • American Society of Clinical Oncology

  • American Society of Hematology

  • American Society of Bone Marrow Transplantation

  • Foundation for the Accreditation for Cellular Therapy (FACT), Inspector (2012 – Present)

  • FACT Program Relations Committee (2013 – Present)

  • Reviewer for Peer Review Articles: BMT, Blood, BBMT, Leukemia Research, American Journal for Hematology

Past Academic Faculty Appointments

  • Assistant Professor of Medicine, University of Central Florida, Florida Center for Cellular Therapy, Adult Bone Marrow Transplant Physician

  • Medical Director, Florida Hospital Cellular Therapy Laboratory

  • Clinical Director, Florida Center for Cellular Therapy

Publications

  • Authored and co-authored over 260 articles and abstracts in the field of leukemia and stem cell transplantation in peer-reviewed journals: Journal of Clinical Oncology, Blood Advances, Hematologica, Blood Reviews, Biology of Blood and Marrow Transplant, Bone Marrow Transplantation, and the American Journal of Hematology, and has authored several book chapters in the field of leukemia and stem cell transplantation.

Dr. Solh’s clinical research interests include the development of innovative therapies for leukemia and improving the success of allogeneic stem cell transplantation, with a focus on novel approaches, including alternative donor transplantation.